Wells Fargo lowered the firm’s price target on Affimed to $25 from $30 and keeps an Overweight rating on the shares. Following review of company Q4 2023 update, the firm remains optimistic that the Phase 2 LuminICE-203 study of AFM13 + AB-101 can meet the bar set by KOLs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>